Compassionate use of orphan drugs

Orphanet Journal of Rare Diseases

Volumn 10, Issue 1, 2015, Pages

  Hyry, Hanna I ^a   Manuel, Jeremy ^b   Cox, Timothy M ^a   Roos, Jonathan C P ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b European Gaucher Alliance and Gauchers Association   (United Kingdom)

Author keywords

Compassionate use; Ethical and pragmatic arguments; EU; Legal; Orphan drugs

Indexed keywords

ORPHAN DRUG;

ARTICLE; COMMERCIAL PHENOMENA; COMPASSIONATE DRUG USE; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG LEGISLATION; DRUG REGISTRY; DRUG RESPONSE; DRUG USE; ECONOMIC EVALUATION; GAUCHER DISEASE; GOVERNMENT REGULATION; HEALTH CARE ACCESS; HEALTH CARE COST; HUMAN; MARKETING AUTHORIZATION; MEDICAL ETHICS; POSTMARKETING SURVEILLANCE; REGISTER; REIMBURSEMENT; SOCIAL BEHAVIOR; TAX; COMPASSIONATE USE; DRUG MANUFACTURE; EUROPEAN UNION;

COMPASSIONATE USE TRIALS; EUROPEAN UNION; HUMANS; ORPHAN DRUG PRODUCTION;

EID: 84939630744     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/s13023-015-0306-x     Document Type: Article

References (27)

1. Tastemain C. Confusion reigns over compassionate use of AIDS drug. Nat Med. 1995;1(10):986.
2. European Medicines Agency. Pilot project on adaptive licensing. 19 March 2014. [http://www.ema.europa.eu/docs/en-GB/document-library/Other/2014/03/WC500163409.pdf]
3. Degrassat-Théas A, Paubel P, Parent de Curzon O, Le Pen C, Sinègre M. Temporary authorization for use: does the French patient access programme for unlicensed medicines impact market access after formal licensing? Pharmacoeconomics. 2013;31(4):335-43.
4. Hyry HI, Roos JC, Manuel J, Cox TM. The legal imperative for treating rare disorders. Orphanet J Rare Dis. 2013;8:135.
5. Hyry HI, Roos JC, Cox TM. Orphan drugs: expensive yet necessary. QJM. 2015;108:269-72.
6. Roos JC, Hyry HI, Cox TM. Orphan drug pricing may warrant a competition law investigation. BMJ. 2010;341:c6471.
7. European Commission. The Centralised Procedure. [http://ec.europa.eu/health/authorisation-procedures-centralised-en.htm]
8. European Medicines Agency. Guideline on compassionate use of medicinal products, pursuant to Article 83 of Regulation (EC) No 726/2004. [www.ema.europa.eu/docs/en-GB/document-library/Regulatory-and-procedural-guideline/2009/10/WC500004075.pdf]
9. European Medicines Agency. Compassionate use. [www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general-content-000293.jsp]
10. Article 288 (ex Article 249) of the Treaty on the Functioning of the European Union (as amended by the Lisbon Treaty).
11. Fulda CB, Baud EG, Macchi de Cellere S, Delgado M. Compassionate Use in Europe: A Patchy Framework for Early Market Entry. JonesDay Publications 2010 August. [www.jonesday.com/compassionate-use-in-europe-a-patchy-frame-work-for-early-market-entry-08-20-2010/]
12. Whitfield K, Huemer KH, Winter D, Thirstrup S, Libersa C, Barraud B, et al. Compassionate use of interventions: results of a European Clinical Research Infrastructures Network (ECRIN) survey of ten European countries. Trials. 2010;11:104.
13. European Medicines Agency. Information provided as a response to a Freedom of Information Request. 2014.
14. Znidar I, Collin-Histed T, Niemeyer P, Parkkinen J, Lauridsen AG, Zarina S, et al. The European Gaucher Alliance: A survey of member patient organisations' activities, healthcare environments and concerns. Poster presented at the European Working Group on Gaucher Disease. June 2014
15. European Medicines Agency. Questions and answers on the compassionate use of medicines in the European Union. 21 January 2010. [http://www.ema.europa.eu/docs/en-GB/document-library/Other/2010/01/WC500069898.pdf]
16. European Medicines Agency. Conditions of use, conditions for distribution and patients targeted and conditions for safety monitoring addressed to member states for IV Zanamivir available for compassionate use. 23 June 2011. [www.ema.europa.eu/docs/en-GB/document-library/Other/2010/02/WC500074124.pdf]
17. Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31st March 2004 laying down community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. Article 83(8). [ http://eur-lex.europa.eu/LexUriServ.do?uri=OJ:L:2004:136:0001:0033:en:PDF ]
18. Hollak CE, vom Dahl S, Aerts JM, Belmatoug N, Bembi B, Cohen Y, et al. Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. Blood Cells Mol Dis. 2010;44(1):41-7.
19. Association of the British Pharmaceutical Industry. Rules of the Constitution. [ www.abpi.org.uk/about-us/membership/Documents/ABPI%20Rules%20of%20the%20Constitution.pdf ]
20. Jack A, Hope K. Greek crisis gets under skin of vulnerable. Financial Times 2012, May 23. [www.ft.com/cms/s/0/d1cc3256-78c3-11e1-9f49-00144feab49a.html#axzz355BYhs8g]
21. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-4.
22. Hyry HI, Stern AD, Cox TM, Roos JC. Limits on use of health economic assessments for rare diseases. QJM. 2014;107(3):241-5.
23. Wenar L. Why Rawls is not a cosmopolitan egalitarian. In: Martin R, Reidy DA, editors. Rawls's Law of Peoples: A Realistic Utopia? Oxford: Blackwell Publishing; 2006. p. 95-113.
24. Sandel M. Justice. London: Penguin; 2010.
25. Aristotle. Nicomachean Ethics. Crisp R (ed). Cambridge: Cambridge University Press; 2000.
26. Schwartz T, Porath C. Why you hate work. The New York Times Sunday Review. 2014, June 1. page SR1. [www.nytimes.com/2014/06/01/opinion/sunday/why-you-hate -work.html?-]
27. European Commission. Supporting rare diseases registries and providing a European Platform for rare diseases registration. [http://ec.europa.eu/health/rare-diseases/policy/registries/index-en.htm]